Yabao Pharmaceutical Group's (SHA:600351) subsidiary, Suzhou Yabao Pharmaceutical Research and Development, will conduct phase II clinical trials on its SY-009 capsules after receiving approval from China's National Medical Products Administration, according to a Monday disclosure on the Shanghai Stock Shanghai.
The product, which is being tested as a type 2 diabetes drug, will now be tested as a treatment for functional constipation.
The pharmaceutical company spent 87.2 million yuan on the research and development of the drug.
Shares of the company jumped more than 5% in recent trade.
Price (RMB): ¥6.14, Change: ¥+0.30, Percent Change: +5.14%
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。